Charles River Laboratories (CRL) Morgan Stanley 24th Annual Global Healthcare Conference summary

Leadership transition and strategic direction

• Smooth CEO transition with extensive stakeholder engagement and validation of current strategy, Pathway to Purpose, aimed at accelerating revenue growth and margin expansion.

• CFO highlighted business complexity, unique scientific expertise, and a positive inflection point expected to drive improved financial performance from the second half of 2026.

• Recent portfolio optimization includes divestitures and acquisition of a large NHP farm, positioning for stronger performance.

Demand trends and commercial execution

• Demand is improving, with three consecutive quarters of book-to-bill above one, driven by both industry recovery and internal sales force reorganization.

• Small and mid-sized biopharma clients are key growth drivers, with broad-based strength across North America and Europe.

• Proposal and booking rates are rising, with a typical lag of about two quarters from funding to revenue realization.

• Large pharma clients are focused on accelerating programs into the clinic and commercialization, shifting away from cost-cutting.

Market and operational insights

• Complex modalities and increased bioanalytical testing are boosting demand; AI adoption is expected to be a future tailwind.

• Pricing remains stable, with expectations for improvement as capacity fills, but revenue impact will lag due to contract cycles.

• Net book-to-bill above one is targeted for sustainable growth; recent high figures reflect backlog rebuilding rather than immediate revenue spikes.